Zydis selegiline in the management of Parkinson's disease

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 15, 2007, Pages 2615-2624

  Poston, Kathleen L ^a   Waters, Cheryl ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

MAO B inhibitor; Motor fluctuation; Parkinson's disease; Zydis selegiline

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; CIMETIDINE; CIPROFLOXACIN; CYTOCHROME P450; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; FLUVOXAMINE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; RASAGILINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TYRAMINE;

ACCIDENTAL INJURY; ANXIETY DISORDER; AREA UNDER THE CURVE; BACKACHE; BLISTER PACK; CLINICAL TRIAL; DEPRESSION; DISEASE EXACERBATION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; FIRST PASS EFFECT; FREEZE DRYING; HALLUCINATION; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INSOMNIA; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; NEUROPROTECTION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PHARMACODYNAMICS; PNEUMONIA; PSYCHOSIS; QT INTERVAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TABLET DISINTEGRATION; TABLET FORMULATION; THORAX PAIN; UNIFIED PARKINSON DISEASE RATING SCALE; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTIPARKINSON AGENTS; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SELEGILINE; TECHNOLOGY, PHARMACEUTICAL;

EID: 35649002609     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.15.2615     Document Type: Review

References (60)

1. HAMPTON T: Parkinson disease registry launched. JAMA (2005) 293(2):149.
2. TANNER CM, ASTON DA: Epidemiology of Parkinson's disease and akinetic syndromes. Curr. Opin. Neurol. (2000) 13:427-430.
3. HORNYKIEWICZ O: Biochemical aspects of Parkinson's disease. Neurology (1998) 51(Suppl. 2):S2-S9.
4. BRAAK H, GHEBREMEDHIN E, RUB U, BRATZKE H, TREDICI KD: Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. (2004) 318:121-234.
5. GASSER T. Genetics of Parkinson's disease. Curr. Opin. Neurol. (2005) 18:363-369.
6. CHAUDHURI A, BOWLING K, FUNDERBURK C et al.: Interaction of genetic and environmental factors in a Drosophila Parkinsonism model. J. Neurosci. (2007) 27(10):2457-2467.
7. AHLSKOG JE, MUENTER MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Move. Disord. (2001) 16(3):448-458.
8. VAN GERPEN JA, KUMAR N, BOWER JH, WEIQAND S, AHLSKOG JE: Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted county, Minnesota, 1976 - 1990. Arch. Neurol. (2006) 63:205-209.
9. CEDARBAUM JM, TOY LH, GREEN-PARSONS A: L-Deprenyl (selegiline) added to sinemet CR in the management of Parkinson's disease patients with motor response fluctuations. Clin. Neuropharmacol. (1991) 14(3):228-234.
10. YOUDIM MB, BAKHLE Y: Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br.J. Pharmacol. (2006) 147:S287-S296.
11. PALHAGEN S, HEINONEN E, HAGGLUND J et al.: Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson study group. Neurology (1998) 51(2):520-525.
12. MYLLYLA VV, SOTANIEMI KA, HAKULINEN P, MAKI-IKOLA O, HEINONEN E: Selegiline as the primary treatment of Parkinson's - a long-term double blinded study. Acta Neurol. Scand. (1997) 95(4):211-218.
13. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson study group. Arch. Neurol. (1989) 46(10):1052-1060.
14. FERNANDEZ HH, CHEN JJ: Monoamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin. Neuropharmacol. (2007) 30(3):150-168.
15. SHOULSON I: Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson study group. Acta Neurol. Scand Suppl. (1989) 126:171-175.
16. OLANOW C, HAUSER R, GAUGER L et al.: The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann. Neurol. (1995) 38:771-777.
17. MAO-B inhibitors for the treatment of Parkinson's disease. Move. Disorders. (2002) 17(Suppl. 4):S38-S44.
18. SHOULSON I, OAKES D, FAHN S et al.: Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of Parkinsonism trial. Ann. Neurol. (2002) 51:604-612.
19. PALHAGEN S, HEINONEN E, HAGGLUND J et al.: Selegiline slows the progression of the symptoms of Parkinson's disease. Neurology (2006) 66(8):1200-1206.
20. LEES A: Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's disease research group of the United Kingdom. BMJ (1995) 331:1602-1607.
21. LARSEN J, BOAS J: The effeccs of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of the Norwegian-Danish 5-year study. Norwegian-Danish study group. Move. Disord. (1997) 12:173-182.
22. GOLBE LI, LIEBERMAN AN, MUENTER MD et al.: Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin. Neuropharmacol (1988) 11(1):45-55.
23. HUBBLE JP, KOLLER WC, WATERS CH: Effects of selegiline dosing on motor fluctuations in Parkinson's disease. Clin. Neuropharmacol. (1993) 16(1):83-87.
24. PAHWA R, FACTOR D, LYONS K et al.: Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence based review): report of the quality standards subcommittee of the American academy of neurology. Neurology (2006) 66:983-995.
25. HORSTINK M, TOLOSA E, BONUCCELLI U et al.: Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European federation of neurological societies (EFNS) and the movement disorders society-European section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur. J. Neurol. (2006) 13:1186-1202.
26. LIEBERMAN AN, GOPINATHAN G, NEOPHYTIDES AN, FOO S-H: Deprenyl versus placebo in Parkinson's disease. A double-blind study. NY State J. Med. (1987) 87:646-649.
27. KNOLL J: The pharmacology of (-)deprenyl. J. Neural Trans. Suppl. (1986) 22:75-89.
28. MAHMOOD I: Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin. Pharmacokinet. (1997) 33(2):91-102.
29. PICKAR D, COHEN R, JIMERSON D, DL M: Tyramine infusions and selective monoamine oxidase inhibitor treatment. I. Changes in pressor sensitivity. Psychopharmacology (1981) 74(1):4-7.
30. FUH J-L, LEE R-C, WANG S-J et al.: Swallowing difficulty in Parkinson's disease. Clin. Neurol. Neurosurg. (1997) 99:106-112.
31. LEOPOLD N, KAGEL M: Prepharyngeal dysphagia in Parkinson's disease. Dysphagia (1996) 11:14-22.
32. SEAGER H: Drug-delivery products and the Zyclis fast-dissolving dosage form. J. Pharmacy Pharmacol. (1998) 50(4):375-382.
33. EISENHOFER G, KOPIN IJ, GOLDSTEIN DS: Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev. (2004) 56:331-349.
34. CLARKE A, BREWER F, JOHNSON ES et al.: A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J. Neural Trans. (2003) 110:1241-1255.
35. BLACKWELL B: Hypertensive crisis due to monoamine oxidase inhibitors. Lancet (1963) 282(7313):849-851.
36. BLACKWELL B, MABBITT L: Tyramine in cheese related to hypertensive crises after monoamine-oxidase inhibition. Lancet (1965) 285(7392):938-940.
37. DEMARCAIDA JA, SCHWID SR, WHITE WB et al.: Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Move. Disord. (2006) 21(10):1716-1721.
38. EBADI M, SHARMA S, SHAVALI S, EL REFAEY H: Neuroprotective actions of selegiline. J. Neurvsci. Res. (2002) 67:285-289.
39. MYTILINEOU C, COHEN G: Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium. J. Neurochem. (1985) 45:1951-1953.
40. MYTILINEOU C, RADCLIFFE P, OLANOW CW: L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J. Neurochem. (1997) 68:434-436.
41. AM OB, AMIT T, YOUDIM MB: Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett. (2004) 355:169-172.
42. ABU-RAYA S, TABAKMAN R, BLAUGRUND E, TREMBOVLER V, LAZAROVICI P: Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC 12 cells. Eur. J. Pharmacol. (2002) 434:109-116.
43. PATERSON I, JUORIO A, BOULTON A: 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? J. Neurochem. (1990) 55(6):1827-2837.
44. CHEN JJ, SWOPE DM: Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J. Clin. Pharmacol. (2005) 45:878-894.
45. CLARKE A, JOHNSON ES, MALLARD N et al.: A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J. Neural Trans. (2003) 110:1257-1271.
46. HIDESTRAND M, OSCARSON M, SALONEN JS et al.: CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metabol. Dispos. (2001) 29(11):1480-1484.
47. WATERS CH, SETHI KD, HAUSER RA et al.: Zyclis selegiline reduces Off Time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Move. Disord. (2004) 19(4):426-432.
48. ONDO W: Pooled analysis of two identical Phase-III studies of a novel selegiline preparation as adjunctive therapy for Parkinson's disease. Move. Disor. Abstr. First World Parkinson Congress (2006) 21(Suppl. 13):S126.
49. LEW MF, PAHWA R, LEEHEY M et al.: Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease. Curr. Med. Res. Opin. (2007) 23(4):741-750.
50. GILLMAN P: Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br. J. Anasth. (2005) 95(4):434-441.
51. LEW MF, SETHI KD, KRICORIAN G: Safety of zelapar (selegiline orally disintegrating tablet) with concomitant antidepressant therapy in Parkinson's disease (PD). 11th International Congress of Parkinson's Disease and Movement Disorders. Istanbul, Turkey (2007):(Poster 337).
52. OLDFIELD V, KEATING GM, PERRY CM: Rasagiline: a review of its use in the management of Parkinson's disease. Drugs (2007) 67(12):1725-1747.
53. PARKINSON STUDY GROUP: A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Parkinson study group. Arch. Neurol. (2002) 59:1937-1943.
54. SIDEROWF A, STERN M: Clinical trials with rasagiline: evidence for short-term and long-term effects. Neurology (2006) 66(Suppl. 10):S80-S88.
55. PARKINSON STUDY GROUP: A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Parkinson's study group. Arch. Neurol. (2005) 62:241-248.
56. RASCOL O, BROOKS D, MELAMED E et al.: Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet (2005) 365:947-954.
57. OLANOW CW, MYLLYLA VV, SOTANIEMI KA et al.: Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology (1998) 51(3):825-830.
58. MIYAZAKI Y, ARAKAWA M, KIZU J: Introduction of simple swallowing ability test for the prevention of aspiration pneumonia in the elderly and investigation of factors of swallowing disorders. Pharmaceut. Soc. Japan (2002) 122(1):97-105.
59. BARONE P, AMBONI M, VITALE C, BONAVITA V: Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson's disease. Neurology (2004) 63(Suppl. 8):S35-S38.
60. TATTON W, WADIA J, JU W: (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J. Neural Trans. Suppl. (1996) 48:45-49.